Tuesday, April 1, 2025
4/1/2025
Development of Best-in-Class Pol-Theta Inhibitors - Project summary. BRCA1 and BRCA2 facilitate DNA double-strand break (DSB) repair via homologous recombination (HR). Yet BRCA1/2 are often mutated in cancers, such as breast/ovarian/prostate/pancreatic carcinomas. BRCA-deficient cancer cells are therefore HR-defective, and susceptible to agents that induce DNA damage and/or prevent DSB repair. For instance, Poly-ADP ribose polymerase 1 (PARP1) inhibitors (PARPi) preferentially kill BRCA-deficient cancer cells and are approved to treat HR-deficient cancers. However, only ~60% patients respond to PARPi and drug resistance is a major problem. Thus, developing second-generation precision medicines that target HR-deficient cancers and/or overcome PARPi resistance is urgently needed. DNA polymerase theta (Polq), a DNA repair factor important for microhomology-mediated end-joining (MMEJ) of DSBs, has been recently validated as a druggable target in BRCA-deficient cancers. Polq is essential for BRCA-deficient cancer cells, but is dispensable for BRCA-proficient cells, and Polq null mice exhibit no major phenotypes. Recently reported Polq inhibitors (Polqi) showed preferential killing of BRCA-deficient cells. Yet, these early stage inhibitors have significant deficiencies (i.e. poor ADME and PK parameters, or low potency) which may limit their efficacy in clinical studies. We have developed a novel, oral bioavailable Polqi that exhibits 5.1 nM IC50 against Polq polymerase (Polq-pol), selectively kills BRCA-deficient cells, and exhibits better pharmacokinetics than recently published Polqi. Our collaborative team (Pomerantz, Johnson, and Childers labs) plans to further improve and demonstrate proof-of-principle of our novel Polqi as the potentially best-in-class Polqi by developing the following Aims: 1. Optimization of Polqi via a prodrug strategy; 2. Biochemical and cellular characterization of Polqi; 3. In vivo efficacy of optimized Polqi in BRCA-deficient solid tumors. We expect that successful completion of these Aims will enable the development of a potentially best-in-class Polqi prodrug candidate.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).